BPI-361175

N/A

Report date: 2026/04/30 20:00:20
NME

Base Information

Drug NameBPI-361175
Drug Alias NameBPI-361175
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR C797S inhibitorsEpidermal growth factor receptor erbB1 inhibitors
TargetsEpidermal growth factor receptor erbB1EGFR C797S
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPending
Originator CompaniesBetta Pharmaceuticals Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesXcovery Holdings,IncBetta Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A